Characterize Merging HIV Strains from Blood Donors and Patients

描述来自献血者和患者的合并 HIV 毒株的特征

• 批准号: 10383884
• 负责人: INDIRA HEWLETT
• 金额: $ 18万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10383884
• 关键词: Agreement; Biological Assay; Blood donor; Cameroon; Detection; Diagnostic; Enzyme-Linked Immunosorbent Assay; Genes; Genotype; Gold; HIV; HIV-1; National Institute of Allergy and Infectious Disease; Patients; Performance; Pharmaceutical Preparations; Plasma; Research; Specimen; Virus; Work; base; diagnostic assay; genome sequencing; repository; vaccine trial

The purpose of this agreement is to continue research at the FDA lab on HIV characterization studies for NIAID’s efforts to develop a well-characterized, dynamic repository of diverse HIV strains for diagnostics, drug and vaccine studies. To accomplish this, CBER and NIAID will collaborate in the work of characterizing these diverse strains and using a subset of viruses and plasma to develop globally diverse panels for evaluating performance of HIV diagnostic assays.

本协议的目的是在FDA实验室继续研究HIV表征研究，以开发用于诊断，药物和疫苗研究的各种HIV菌株的特征良好的动态储存库。为此，CBER和NIAID将在表征这些潜水员菌株并使用病毒和等离子体的子集来开发全球多样的面板以评估HIV诊断测定的性能。